news

 

Cyril Amarchand Mangaldas has advised PE firm Warburg Pincus on its acquisition of housing finance company Shriram Housing Finance (SHF) for 46.3 billion rupees ($556 mln) from Shriram Finance and Valiant Partners.

Shriram Finance was represented by Trilegal, while Anagram Partners counselled Valiant Partners.

Warburg Pincus will acquire the stake through its affiliate, Mango Crest Investment, from both sellers. The deal is Warburg’s largest in the Indian market.

The existing management team of SHF, led by Ravi Subramanian, managing director and chief executive officer, will continue to lead the business.

“Warburg Pincus remains excited about the affordable housing finance segment in India,” Narendra Ostawal, head of India private equity, Warburg Pincus, said in a statement.

CAM’s team was led by corporate partners Shishir Vayttaden and Aditi Singhvi, and included senior associate Reeti Agarwal and associate Suyashi Mishra. Partners Subhojit Sadhu (finance), Abe Abraham (employment), Avaantika Kakkar (competition), Anirban Mohapatra (intellectual property), Bharat Reddy (corporate), and Indranath Bishnu (insurance) assisted on the deal.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Top CAM dealmaker rocks market with move to Khaitan

by Nimitt Dixit |

Top Indian dealmaker Shishir Vayttaden has left the equity partnership at Cyril Amarchand Mangaldas to join Khaitan & Co, along with two other partners in his team, K. Aishwarya and Aditi Singhvi.

White & Case guides $380mln U.S.-Japan LNG deal

by Nimitt Dixit |

Global law firm White & Case has advised Japan Petroleum Exploration Co. (JAPEX) on the acquisition through its U.S. subsidiary of an equity interest in Gulf Coast LNG Holdings, which owns an interest in the Freeport LNG project in Texas, from JERA Americas for approximately $380 million.

Reed Smith, Freshfields, Kirkland on Henlius’ $691 mln take-private deal

Freshfields Bruckhaus Deringer is representing Hong Kong-listed biotech company Henlius on its $691 million take-private deal offer from Shanghai Fosun New Medicine Research Company, which is being advised by Reed Smith.